Dose regimen for administration of LAG-3/PD-L1 bispecific antibodies
The present application relates to dosage regimens for the administration of antibody molecules that bind programmed death-ligand 1 (PD-L1) and lymphocyte activation gene 3 (LAG-3) and their medical use in the treatment of cancer in human patients. 本申请涉及用于结合程序性死亡-配体1(PD-L1)和淋巴细胞活化基因3(LAG-3)的抗体分子的施用的...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | GLIDDEN DANIEL HOLTZ JOSEPHINE-BEATE CATALIER, LOUIS GRADINARU CRISTIAN MOREAU MICHEL ZIEMASCZEWSKI, FIONA SHEPHERD CHRISTOPHER LIANG JIANMEI |
| description | The present application relates to dosage regimens for the administration of antibody molecules that bind programmed death-ligand 1 (PD-L1) and lymphocyte activation gene 3 (LAG-3) and their medical use in the treatment of cancer in human patients.
本申请涉及用于结合程序性死亡-配体1(PD-L1)和淋巴细胞活化基因3(LAG-3)的抗体分子的施用的剂量方案及它们在人类患者癌症的治疗中的医学用途。 |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN114206939A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN114206939A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN114206939A3</originalsourceid><addsrcrecordid>eNrjZHBxyS9OVShKTc_MTc1TSMsvUkhMyc3MyywuKUosyczPU8hPU_BxdNc11g9w0fUxVEjKLC5ITc5My0xWSMwryUzKT8lMLeZhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfHOfoaGJkYGZpbGlo7GxKgBAAUUMVk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Dose regimen for administration of LAG-3/PD-L1 bispecific antibodies</title><source>esp@cenet</source><creator>GLIDDEN DANIEL ; HOLTZ JOSEPHINE-BEATE ; CATALIER, LOUIS ; GRADINARU CRISTIAN ; MOREAU MICHEL ; ZIEMASCZEWSKI, FIONA ; SHEPHERD CHRISTOPHER ; LIANG JIANMEI</creator><creatorcontrib>GLIDDEN DANIEL ; HOLTZ JOSEPHINE-BEATE ; CATALIER, LOUIS ; GRADINARU CRISTIAN ; MOREAU MICHEL ; ZIEMASCZEWSKI, FIONA ; SHEPHERD CHRISTOPHER ; LIANG JIANMEI</creatorcontrib><description>The present application relates to dosage regimens for the administration of antibody molecules that bind programmed death-ligand 1 (PD-L1) and lymphocyte activation gene 3 (LAG-3) and their medical use in the treatment of cancer in human patients.
本申请涉及用于结合程序性死亡-配体1(PD-L1)和淋巴细胞活化基因3(LAG-3)的抗体分子的施用的剂量方案及它们在人类患者癌症的治疗中的医学用途。</description><language>chi ; eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220318&DB=EPODOC&CC=CN&NR=114206939A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220318&DB=EPODOC&CC=CN&NR=114206939A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GLIDDEN DANIEL</creatorcontrib><creatorcontrib>HOLTZ JOSEPHINE-BEATE</creatorcontrib><creatorcontrib>CATALIER, LOUIS</creatorcontrib><creatorcontrib>GRADINARU CRISTIAN</creatorcontrib><creatorcontrib>MOREAU MICHEL</creatorcontrib><creatorcontrib>ZIEMASCZEWSKI, FIONA</creatorcontrib><creatorcontrib>SHEPHERD CHRISTOPHER</creatorcontrib><creatorcontrib>LIANG JIANMEI</creatorcontrib><title>Dose regimen for administration of LAG-3/PD-L1 bispecific antibodies</title><description>The present application relates to dosage regimens for the administration of antibody molecules that bind programmed death-ligand 1 (PD-L1) and lymphocyte activation gene 3 (LAG-3) and their medical use in the treatment of cancer in human patients.
本申请涉及用于结合程序性死亡-配体1(PD-L1)和淋巴细胞活化基因3(LAG-3)的抗体分子的施用的剂量方案及它们在人类患者癌症的治疗中的医学用途。</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHBxyS9OVShKTc_MTc1TSMsvUkhMyc3MyywuKUosyczPU8hPU_BxdNc11g9w0fUxVEjKLC5ITc5My0xWSMwryUzKT8lMLeZhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfHOfoaGJkYGZpbGlo7GxKgBAAUUMVk</recordid><startdate>20220318</startdate><enddate>20220318</enddate><creator>GLIDDEN DANIEL</creator><creator>HOLTZ JOSEPHINE-BEATE</creator><creator>CATALIER, LOUIS</creator><creator>GRADINARU CRISTIAN</creator><creator>MOREAU MICHEL</creator><creator>ZIEMASCZEWSKI, FIONA</creator><creator>SHEPHERD CHRISTOPHER</creator><creator>LIANG JIANMEI</creator><scope>EVB</scope></search><sort><creationdate>20220318</creationdate><title>Dose regimen for administration of LAG-3/PD-L1 bispecific antibodies</title><author>GLIDDEN DANIEL ; HOLTZ JOSEPHINE-BEATE ; CATALIER, LOUIS ; GRADINARU CRISTIAN ; MOREAU MICHEL ; ZIEMASCZEWSKI, FIONA ; SHEPHERD CHRISTOPHER ; LIANG JIANMEI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN114206939A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>GLIDDEN DANIEL</creatorcontrib><creatorcontrib>HOLTZ JOSEPHINE-BEATE</creatorcontrib><creatorcontrib>CATALIER, LOUIS</creatorcontrib><creatorcontrib>GRADINARU CRISTIAN</creatorcontrib><creatorcontrib>MOREAU MICHEL</creatorcontrib><creatorcontrib>ZIEMASCZEWSKI, FIONA</creatorcontrib><creatorcontrib>SHEPHERD CHRISTOPHER</creatorcontrib><creatorcontrib>LIANG JIANMEI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GLIDDEN DANIEL</au><au>HOLTZ JOSEPHINE-BEATE</au><au>CATALIER, LOUIS</au><au>GRADINARU CRISTIAN</au><au>MOREAU MICHEL</au><au>ZIEMASCZEWSKI, FIONA</au><au>SHEPHERD CHRISTOPHER</au><au>LIANG JIANMEI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Dose regimen for administration of LAG-3/PD-L1 bispecific antibodies</title><date>2022-03-18</date><risdate>2022</risdate><abstract>The present application relates to dosage regimens for the administration of antibody molecules that bind programmed death-ligand 1 (PD-L1) and lymphocyte activation gene 3 (LAG-3) and their medical use in the treatment of cancer in human patients.
本申请涉及用于结合程序性死亡-配体1(PD-L1)和淋巴细胞活化基因3(LAG-3)的抗体分子的施用的剂量方案及它们在人类患者癌症的治疗中的医学用途。</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN114206939A |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Dose regimen for administration of LAG-3/PD-L1 bispecific antibodies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T17%3A39%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GLIDDEN%20DANIEL&rft.date=2022-03-18&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN114206939A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |